Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTLaiba ImmadTue, August 11, 2026 at 2:22 PM GMT+2 4 min readIt was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year revenue surge to $496.0 million, profit-taking took hold after a massive year-to-date rally.The second-quarter revenue growth was anchored by $411.7 million in proprietary net sales. Key commercial contributors included VIVITROL ($124.5 million), ARISTADA ($96.7 million), and LYBALVI ($94.0 million, up 12% year-over-year). The newly integrated narcolepsy therapy LUMRYZ generated $96.6 million in net sales, which included an estimated $7 million inventory timing benefit. Manufacturing and royalty revenues added $79.0 million, led by VUMERITY ($30.6 million) and the INVEGA/XEPLION franchise ($27.5 million).However, GAAP net income fell to $0.5 million from $87.1 million in Q2 2025, heavily impacted by integration expenses and stepped-up R&D/SG&A investments, even as Adjusted EBITDA grew to $139.2 million. The company also announced a leadership transition: long-time CEO Richard Pops will transition to Executive Chairman, passing the CEO role to Chief Operating Officer Blair Jackson from August 1.Now, the question that arises is whether this pull-back a temporary pause for an expanding neuroscience commercial platform, or does the margin compression signal deeper integration risks?Could Alkermes plc (ALKS)Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?BULL CASEAlkermes plc (NASDAQ:ALKS) maintains exceptionally strong profitability, with gross margins consistently in the mid-80% range across its proprietary product portfolio. This margin profile supported adjusted EBITDA of $139.2 million in the second quarter, highlighting the company's ability to generate meaningful earnings while funding internal research and development as well as commercial expansion without relying heavily on shareholder dilution.The company's commercial business also remains well diversified, with steady performance from its established psychiatric and addiction treatments, including Vivitrol, Aristada, and Lybalvi. The addition of LUMRYZ has expanded Alkermes' presence into the sleep medicine market, reducing dependence on any single product while strengthening its commercial infrastructure and creating additional long-term growth opportunities.Financially, ALKS continues to benefit from positive operating and free cash flow, giving it a self-funding balance sheet and significant financial flexibility. Beyond its existing portfolio, the company's pipeline provides multiple high-value catalysts, including upcoming ADHD data for ALKS 7290 and Phase 2 topline results for the orexin 2 receptor agonist alixorexton in idiopathic hypersomnia, both of which could serve as important long-term growth drivers.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info